BioSeek Extends Collaboration with Merck Serono (2161A)
March 28 2012 - 2:00AM
UK Regulatory
TIDMATD
RNS Number : 2161A
Asterand PLC
28 March 2012
Asterand's Subsidiary BioSeek Extends Collaboration with Merck
Serono
New Three-Year Deal Provides Merck Serono Expanded Access to
BioSeek LLC's BioMAP(R) Platform
SOUTH SAN FRANCISCO, CA, USA (March 28, 2012) - BioSeek, LLC, a
subsidiary of Asterand plc (LSE: ATD), a pioneer in the application
of predictive human biology to drug discovery, announced today that
it has signed a new, three-year collaboration agreement with Merck
Serono, a division of Merck KGaA, Darmstadt, Germany. The new
agreement extends and expands the companies' previous three-year
agreement from 2009. Under the new research plan, BioSeek will
expand the use of its proprietary BioMAP platform to evaluate Merck
Serono small molecule compounds and proteins across multiple
therapeutic areas in support of target differentiation, lead
selection and optimization and nomination of candidates for
preclinical development at Merck Serono.
Jack Davis, Chairman and Interim Chief Executive Officer of
Asterand commented:
"We highly value our long-standing relationship with Merck
Serono. The studies carried out by BioSeek for Merck Serono over
the past three years have demonstrated that BioMAP Platform can be
used to reliably advance promising molecules through preclinical
evaluation. Our scientists have worked closely and productively
with the Merck Serono team, and we look forward to our continuing
and expanding research with them".
BioMAP(R) Systems are primary cell-based models of human disease
biology, designed to replicate the intricate cell and pathway
interactions as they are observed in human pharmacology and
toxicology. Depending on their mechanism of action, compounds
induce specific patterns of changes in these systems (BioMAP(R)
profiles) that can be compared to a large number of reference
profiles in the BioMAP(R) Database. Assessment with BioMAP(R)
provides early insight into human pharmacological and toxicological
properties of compounds, including on-and off-target effects, dose
responses, and the discrimination of closely related compounds.
About BioSeek
BioSeek, LLC, is a wholly owned subsidiary of Asterand plc (LSE:
ATD), a leading supplier of high quality human tissue and
tissue-based services. BioSeek improves the success rate of
pharmaceutical research and development by integrating human
biology from the earliest stages of drug discovery onward through
its unique BioMAP(R) predictive human-based models. Our mission is
to accelerate target discovery and drug compound validation and
enable our clients to take safer and more effective drugs into the
market.
For more information about Asterand and BioSeek, please visit
http://www.asterand.com.
Contacts
BioSeek LLC (Asterand plc) Tel: +1 (650) 416 7629
Ivan Plavec, VP Business Development
Daniel Stewart & Company plc
Antony Legge Tel: +44 (0) 20 7776 6550
David Hart
Paul Shackleton
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAPDXASSAEFF
Bioseek (LSE:ATD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioseek (LSE:ATD)
Historical Stock Chart
From Jul 2023 to Jul 2024